Provider Briefing: Bismuth Subcitrate/Metronidazole/Tetracycline Supply in 2026

For gastroenterologists, internists, and primary care providers prescribing bismuth quadruple therapy, the availability of Bismuth Subcitrate/Metronidazole/Tetracycline (Pylera) continues to be a practical challenge. While not in a formal FDA shortage, this combination medication remains intermittently difficult for patients to fill — creating downstream complications for treatment adherence and clinical outcomes.

This article provides a concise update on the current supply landscape, prescribing considerations, cost and access factors, and actionable resources to support your patients.

Timeline: How We Got Here

Understanding the supply history helps frame current availability:

• 2006: FDA approves Pylera (Allergan) as the first and only single-capsule bismuth quadruple therapy for H. pylori eradication in duodenal ulcer patients.
• 2006–2022: Allergan (later acquired by AbbVie) remains the sole manufacturer. Periodic supply disruptions occur due to the single-source vulnerability.
• March 2023: Par Pharmaceutical (Endo) launches the first generic version, adding a second supplier to the market.
• 2023–present: Availability improves but remains inconsistent by region and pharmacy chain. Generic uptake grows steadily.

As of early 2025, Bismuth Subcitrate/Metronidazole/Tetracycline was not listed on the FDA Drug Shortage Database. However, anecdotal reports from pharmacies and patient feedback indicate that localized supply gaps persist.

Prescribing Implications

The intermittent availability of Pylera and its generic has several clinical implications providers should consider:

Adherence Concerns

When patients encounter pharmacy-level stockouts, treatment initiation may be delayed by days — or patients may abandon the prescription entirely. For H. pylori eradication, timely treatment completion is critical. Delays can allow bacterial regrowth and potentially contribute to antibiotic resistance.

Patient Communication

Proactively informing patients that this medication may require extra effort to locate can set realistic expectations and improve follow-through. Consider:

• Advising patients to check availability before leaving the office (or using a tool like Medfinder for Providers)
• Providing a backup prescription (e.g., traditional quadruple therapy components) in case the combination capsule isn't available
• Discussing the generic option explicitly, as some pharmacies may default to brand-only searches

E-Prescribing Considerations

When e-prescribing, consider specifying "generic substitution permitted" and including a note that either brand or generic Bismuth Subcitrate Potassium/Metronidazole/Tetracycline Hydrochloride is acceptable. This gives the dispensing pharmacy maximum flexibility.

Current Availability Picture

The availability situation in 2026 can be characterized as follows:

• Brand-name Pylera (AbbVie): Available but distribution may be limited to certain wholesalers and pharmacies
• Generic (Par Pharmaceutical): More widely distributed, increasingly stocked at chain and independent pharmacies
• Regional variability: Availability can differ significantly by geography and pharmacy chain. Urban areas with multiple pharmacy options generally have better access.
• Mail-order pharmacies: Often a reliable alternative when local pharmacies are out of stock

Cost and Access Considerations

Cost remains a significant barrier for uninsured and underinsured patients:

• Brand-name Pylera: $900–$1,181 retail for a 10-day course (120 capsules)
• Generic (retail): $305–$500
• Generic with discount coupon: As low as $187 (GoodRx, SingleCare)
• Traditional quadruple therapy (separate pills): Often under $50 for all three generics plus OTC Bismuth Subsalicylate

For patients facing cost barriers, traditional quadruple therapy with separately prescribed components is often the most accessible and affordable option. The AbbVie/Allergan Patient Assistance Program may provide brand-name Pylera at no cost for qualifying patients (contact: 1-800-347-4500 or abbvieaccess.com).

For a patient-facing guide on cost savings, consider sharing our article on saving money on Bismuth Subcitrate/Metronidazole/Tetracycline.

Tools and Resources for Providers

Several tools can help streamline the prescribing and dispensing process:

• Medfinder for Providers: Real-time pharmacy stock checking to help patients find Bismuth Subcitrate/Metronidazole/Tetracycline near them before they leave your office.
• FDA Drug Shortage Database: Monitor for any formal shortage listings at accessdata.fda.gov
• ASHP Drug Shortage Resource Center: Additional shortage tracking and clinical guidance
• AbbVie Access: Manufacturer resources including patient assistance programs

Clinical Alternatives When Pylera Is Unavailable

When Bismuth Subcitrate/Metronidazole/Tetracycline cannot be obtained, the following evidence-based alternatives are available:

1. Traditional bismuth quadruple therapy: Bismuth Subsalicylate + Metronidazole + Tetracycline + PPI (same drugs, separate pills — widely available and affordable)
2. Concomitant therapy: PPI + Amoxicillin + Clarithromycin + Metronidazole (effective where dual resistance is uncommon)
3. Rifabutin triple therapy (Talicia): Omeprazole + Amoxicillin + Rifabutin (valuable for salvage therapy or areas with high Clarithromycin resistance)
4. Vonoprazan-based regimens (Voquezna): Newer option with potassium-competitive acid blocker, approved 2023

Current ACG guidelines recommend bismuth quadruple therapy and concomitant therapy as preferred first-line regimens. The choice between them should be guided by local resistance patterns and patient-specific factors.

For more on alternatives, see our clinical overview on alternatives to Bismuth Subcitrate/Metronidazole/Tetracycline.

Looking Ahead

Several developments may further improve availability and access in the coming years:

• Additional generic approvals: More manufacturers entering the market would increase supply resilience.
• Vonoprazan adoption: As Vonoprazan-based regimens gain traction, they may reduce overall demand for bismuth quadruple therapy capsules.
• Supply chain improvements: Industry-wide efforts to strengthen pharmaceutical supply chains post-pandemic may benefit niche medications like this one.

Final Thoughts

Bismuth Subcitrate/Metronidazole/Tetracycline remains a cornerstone of H. pylori eradication therapy, and its single-capsule formulation offers meaningful adherence advantages. While supply constraints have improved since the 2023 generic launch, providers should be prepared with contingency plans when the combination capsule isn't available.

Proactive communication with patients, familiarity with alternative regimens, and use of tools like Medfinder for Providers can help ensure your patients receive timely, effective H. pylori treatment regardless of pharmacy-level supply fluctuations.

For additional provider resources, see our guide on helping patients find Bismuth Subcitrate/Metronidazole/Tetracycline in stock and helping patients save money on this medication.